Sanofi (SNY) Cash from Restructuring (2009 - 2026)

Sanofi has reported Cash from Restructuring for 18 years, with the latest figure at -$371.1 million in Q1 2026.

• Quarterly Cash from Restructuring fell 22.93% year-over-year to -$371.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.6 billion (down 0.72% YoY) and the FY2025 annual result came in at -$913.8 million, down 8.66% from the prior year.
• Cash from Restructuring climbed to -$371.1 million in Q1 2026 per SNY's latest filing, from -$913.8 million in the prior quarter.
• Over five years, Cash from Restructuring peaked at -$301.9 million in Q1 2025 and troughed at -$1.1 billion in Q4 2022.
• A 5-year average of -$640.1 million and a median of -$405.2 million in 2022 frame the typical range for Cash from Restructuring.
• The sharpest annual moves came in 2022 and 2023: Cash from Restructuring tumbled 37.66% in 2022, then rose 20.48% in 2023.
• Over 5 years, Cash from Restructuring stood at -$1.1 billion in 2022, then rose by 20.48% to -$913.5 million in 2023, then slipped by 9.03% to -$995.9 million in 2024, then advanced by 8.25% to -$913.8 million in 2025, then jumped by 59.39% to -$371.1 million in 2026.
• According to Business Quant data, Cash from Restructuring over the past three periods registered -$371.1 million, -$913.8 million, and -$301.9 million for Q1 2026, Q4 2025, and Q1 2025 respectively.